The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease
暂无分享,去创建一个
J. Townend | R. Steeds | C. Ferro | P. Stewart | B. Hughes | N. Edwards | F. Hammer | Jonathan N. Townend
[1] J. Townend,et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. , 2009, Journal of the American College of Cardiology.
[2] T. Olsson,et al. Combined receptor antagonist stimulation of the hypothalamic-pituitary-adrenal axis test identifies impaired negative feedback sensitivity to cortisol in obese men. , 2009, The Journal of clinical endocrinology and metabolism.
[3] B. Rutkowski,et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[4] C. Pryce. Postnatal ontogeny of expression of the corticosteroid receptor genes in mammalian brains: Inter-species and intra-species differences , 2008, Brain Research Reviews.
[5] N. Samani,et al. Phenotypic consequences of variation across the aldosterone synthase and 11‐beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study , 2007, Clinical endocrinology.
[6] M. Cooper,et al. 11β-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function* , 2007, Journal of Biological Chemistry.
[7] H. Nagaraja,et al. Usual ACE Inhibitor Therapy in CKD Patients Is Associated with Lower Plasma Aldosterone Levels than Usual Angiotensin Receptor Blocker Therapy , 2007, Kidney and Blood Pressure Research.
[8] Stefan Störk,et al. Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure , 2007, Circulation.
[9] H. Raff,et al. Association of Adrenal Steroids With Hypertension and the Metabolic Syndrome in Blacks , 2007, Hypertension.
[10] F. Manguso,et al. Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. , 2006, The Journal of clinical endocrinology and metabolism.
[11] P. Stewart,et al. Cortisol metabolism in hypertension. , 2006, Best practice & research. Clinical endocrinology & metabolism.
[12] A. Garg,et al. Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.
[13] J. Mann,et al. Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. , 2005, Presse medicale.
[14] D. Zehnder,et al. Expression of renal 11β-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function , 2005 .
[15] T. Mune,et al. [Syndrome of apparent mineralocorticoid excess]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.
[16] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[17] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.
[18] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.
[19] D. Duprez,et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. , 2002, Journal of the American College of Cardiology.
[20] S. Grottoli,et al. The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans. , 2002, The Journal of clinical endocrinology and metabolism.
[21] B. Walker,et al. Glucocorticoid metabolism and the Metabolic Syndrome: associations in an elderly cohort. , 2002, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[22] F. Frey,et al. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. , 2002, Kidney international.
[23] P. Manunta,et al. CA-Repeat polymorphism in intron 1 of HSD11B2 : effects on gene expression and salt sensitivity. , 2000, Hypertension.
[24] A. Charlesworth,et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. , 2000, Circulation.
[25] I. Heuser,et al. Increased activity of the hypothalamus–pituitary–adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone , 2000, Psychoneuroendocrinology.
[26] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[27] F. Frey,et al. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. , 1999, The Journal of clinical endocrinology and metabolism.
[28] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[29] H. Akil,et al. The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans. , 1998, The Journal of clinical endocrinology and metabolism.
[30] M. Joëls,et al. Brain corticosteroid receptor balance in health and disease. , 1998, Endocrine reviews.
[31] C. Shackleton,et al. Urinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man , 1996, Clinical endocrinology.
[32] J. Born,et al. Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans. , 1993, Neuroendocrinology.
[33] J. Mathis,et al. Human NCI-H295 adrenocortical carcinoma cells: a model for angiotensin-II-responsive aldosterone secretion. , 1993, Endocrinology.
[34] F. Holsboer,et al. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. , 1993, Molecular endocrinology.
[35] R. Sapolsky,et al. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. , 1991, Endocrine reviews.
[36] J. Whitworth,et al. THE KIDNEY IS THE MAJOR SITE OF CORTISONE PRODUCTION IN MAN , 1989, Clinical endocrinology.
[37] C. Edwards,et al. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. , 1988, The Journal of clinical investigation.
[38] D. Housman,et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. , 1987, Science.
[39] D. Webb,et al. Measurement of plasma angiotensin II. , 1985, Clinical science.
[40] J. Morton,et al. A microassay for active and total renin concentration in human plasma based on antibody trapping. , 1980, Clinica chimica acta; international journal of clinical chemistry.
[41] W. Sadee,et al. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria. , 1976, Endocrinology.
[42] J. Jarrell,et al. Mechanism of action of spironolactone on adrenocortical function in guinea pigs. , 1976, The Journal of pharmacology and experimental therapeutics.
[43] D. Zehnder,et al. Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function. , 2005, European journal of endocrinology.
[44] B. Pitt,et al. Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[45] E. Arvat,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Mineralocorticoid Receptor Blockade by Canrenoate Increases Both Spontaneous and Stimulated Adrenal Function in Humans* , 2022 .